bioRxivImmunologyPreprint
The solid tumor microenvironment changes the hierarchy of CD155 and CD112 receptors, shaping checkpoint blockade outcome
Valentina CarannanteiD, Karl OlofssoniD, Hanqing ZhangiD, Niklas SandströmiD, Jacopo Maria FontanaiD, Damien ToulleciD, Grace TuryasinguraiD, Birte Hell, Arnika Kathleen WagneriD, Patrick A. SandoziD, Hanna van OoijeniD, Andreas LundqvistiD, Martin WiklundiD, Björn ÖnfeltiD
Abstract
Reproducing a physiologically relevant tumor microenvironment in vitro is essential for developing effective immunotherapeutic treatments. By integrating the use of combinatorial receptor blockade and organoid models we provide a deep functional understanding of CD155 and CD112 receptors in solid tumors and their impact on cellular immunotherapy and infiltration. CD226 showed plasticity in response to the environment, being able to switch between CD155 and CD112 depending on the ligand availability. In addition, CD226 drove NK cell infiltration into tumor tissues via CD155 and CD112 ligation, with CD226-CD112 interaction specifically promoting migration from the periphery to the core. Downregulation of CD155 and TIGIT induced by the tumor microenvironment and previous drug exposure reduced the long-term efficacy of TIGIT blockade. Taken together, our findings point towards using CD112R blockade in primary tumors to simultaneously enhance NK cell killing activity and promote infiltration into the tumor core via CD226 and CD112 interaction. ONE SENTENCE SUMMARYTumors shape the hierarchy of CD155-CD112 receptors, reducing TIGIT blockade efficacy, while CD226 drives NK infiltration and shows binding plasticity
- organism: human
- assay: proteomics
- research focus: cell signaling & trafficking
- research focus: cancer & tumor microenvironment
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Soluble CD155 immune complexes reprogram DNAM-1 signaling to potentiate antitumor immunity
Shota Kinoshita, Tomohei Matsuo, … Kazuko Shibuya·bioRxiv·May 19, 2026
- Adaptive anti-tumor immunity is orchestrated by a population of CCL5-producing tissue-resident NK cells
N. Kirchhammer, M. P. Trefny, … A. Zippelius·bioRxiv·May 27, 2021
- PD-1 suppresses the maintenance of cell couples between cytotoxic T cells and tumor target cells within the tumor
R. Ambler, G. L. Edmunds, … C. Wuelfing·bioRxiv·Oct 16, 2018
- PD-L1 blockade restores CAR T cell activity through IFNγ-regulation of CD163+ macrophages
Y. Yamaguchi, J. Gibson, … S. J. Priceman·bioRxiv·Jan 25, 2022
- Inhibition of KDEL receptors remodels the tumor microenvironment for robust T cell independent tumor regression
Shakti Prasad Pattanayak, Hong Wang, … Boaz Tirosh·Advanced SciencePeer-reviewed·Jun 23, 2026
- The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8+ T cell activity and synergizes with immune check-point inhibitors